CRA was retained by a pharmaceutical company to assist in settlement negotiations with a potential generic competitor. As part of this project, CRA prepared a flexible valuation model to estimate the expected profits from the perspective of the generic competitor under various assumptions. CRA also prepared a decision probability tree analysis to address issues related to litigation risk, acceptable date of generic entry and the impact of an authorized generic.
Trade Secret Litigation Watch: February 2026
In this second installment of the Trade Secret Litigation Watch, CRA’s Intellectual Property team examines emerging trends and case outcomes with an emphasis...